Powered by
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), developers of novel treatments to reduce cholesterol in the bloodstream, announced the United States commercial availability of Nexlizet tablets. Nexlizet is a combination of …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …
CANTON TWP.–MMS Holdings Inc., the contract research organization for the pharmaceutical industry based in Canton Township, announced that its regional operations in South Africa more than doubled in the past …
ROCHESTER—OptimizeRx Corp. (NASDAQ: OPRX), a provider of digital health messaging to consumers for the pharmaceutical industry, reported net income of $406,617 or 3 cents a share, up 45 percent in …